Cancer HorizonsAll NewsBlogsCaregivingDiet and ExerciseFinancialPsychosocialRecipesSexual HealthSide EffectSponsoredSurvivorship
All VideosCURE ConnectionsCURE Expert Connections®CURE Speaking OutCURE TVEducated Patient Sound BitesOn Demand: Webinars
Conference Coverage Conference Listing
CURE AdventuresCURE AwardsEducated Patient In Person EducationEducated Patient Virtual Education
Advocacy GroupsArt GalleryClinical Trial CornerHeal®PartnersPodcastsPublicationsShare Your Story
Subscribe
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
Immunotherapy
LeukemiaLeukemiaLeukemia
Lung CancerLung Cancer
LymphomaLymphomaLymphomaLymphomaLymphoma
Myeloma
Rare CancersRare CancersRare CancersRare Cancers
Sarcoma
Skin CancerSkin Cancer
Thyroid Cancer
Spotlight -
  • Blogs
  • Breast Cancer Webinar Series
  • Cancer Horizons
  • Clinical Trial Corner
  • Heal®
  • Publications
  • Videos
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
Immunotherapy
LeukemiaLeukemiaLeukemia
Lung CancerLung Cancer
LymphomaLymphomaLymphomaLymphomaLymphoma
Myeloma
Rare CancersRare CancersRare CancersRare Cancers
Sarcoma
Skin CancerSkin Cancer
Thyroid Cancer
    • Subscribe
Advertisement

Management of Advanced Non–Small Cell Lung Cancer : Episode 13

Video

November 5, 2021

NSCLC: Preparing Patients for Treatment-Related Side Effects

Author(s):

CURE Media Group

Strategies that can help various health care professionals best mitigate or manage side effects associated with newer treatments in non-small cell lung cancer, such as immunotherapy.

Video Player is loading.
Current Time 0:00
/
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time -0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions settings, opens captions settings dialog
    • captions off, selected

      This is a modal window.

      Beginning of dialog window. Escape will cancel and close the window.

      Text
      Background
      Window
      Font Size
      Text Edge Style
      Font Family

      End of dialog window.

      This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

      EP: 1.Novel-Based Treatment Approaches in NSCLC

      EP: 2.Overcoming Barriers to Lung Cancer Screening

      EP: 3.Education on NSCLC Symptoms and Risk Factors

      EP: 4.Predictive and Prognostic Biomarkers in NSCLC

      EP: 5.Addressing Barriers to Molecular Testing in NSCLC

      EP: 6.Counseling Patients With NSCLC About Molecular Testing

      EP: 7.Tissue and Liquid Biopsies in NSCLC

      EP: 8.Individualized Treatment Decisions for Patients With NSCLC

      EP: 9.PD-L1 Testing in NSCLC

      EP: 10.Repeat Biopsies as NSCLC Progresses

      EP: 11.Immunotherapy for Patients With NSCLC

      EP: 12.Shared Decision-Making in NSCLC

      Now Viewing

      EP: 13.NSCLC: Preparing Patients for Treatment-Related Side Effects

      EP: 14.Rechallenging Therapy in NSCLC

      EP: 15.Adopting Precision Medicine in NSCLC

      Hossein Borghaei, DO, MS: Management of side effects becomes the key part of that initial educational component. We try to provide our patients with some information as to what they’re getting. For instance, we have cards that the patients get when they present for the infusion that say, “You’ve received a checkpoint inhibitor. If you have symptoms such as these and you end up in an emergency department, you should show this card to the emergency department staff so they know what treatments you’ve gotten, or at least have them contact us so we can discuss.”

      I tend to go over the key potential toxicities, like pneumonitis and colitis, talk about what some of the presenting signs and symptoms can be, and encourage the patients to call sooner rather than later, emphasizing that the sooner we know, the more effective our treatment interventions can be to avoid things from getting a lot worse. The education of the patients and family members around these toxicities on what to look for is important.

      Internally, we’ve trained all the physicians who work here and all the fellows. We have educational components and internal websites, so that if a patient calls and has specific symptoms, they can refer to these and direct the patient appropriately for the treatments. We won’t hesitate to see someone who suddenly has a cough that wasn’t there before. That’s the way you mitigate some of the potential toxic side effects of these treatments. I’m curious about what mechanisms you have. I know that at the University of Pennsylvania, you guys have access to multispecialty care regarding management of these toxicities. Can you talk a little about that?

      Charu Aggarwal, M.D., MPH: Absolutely. I have a very similar approach to yours when I’m doing my initial education about what immunotherapy is. I come in with the fact that this is a completely different mechanism of action and that our expected side effects could be very different from what chemotherapy side effects are. I also say it can be global. It could be anything, based on our experience and what we’ve seen in clinical trials, and could affect any part of the body at any time. There isn’t a specific time point that if the patient is past the first X months or X weeks, they’re in the clear. These toxicities can sometimes occur very early, but they can also occur late.

      I say that while most toxicity manifests in the form of fatigue or rash, less than 10% of the time, we may have serious organ-related toxicity, be it, like you said, shortness of breath; inflammation in the colon causing diarrhea; inflammation of the thyroid, which occurs very frequently; or things such as inflammation of the heart.

      We at the University of Pennsylvania have developed a multidisciplinary group of immunotherapy-related side event management where we have a dedicated team of endocrinologists who help us manage refractory cases of hypothyroidism, for example, or difficult cases of hyperthyroidism going into an exhausted state of hypothyroidism. We have dedicated gastroenterologists who can help us manage oral or topical steroids or locally absorbed steroid applications for patients who develop inflammation. We have cardiologists, pulmonologists, and now rheumatologists and neurologists who specialize in this. We unfortunately have had the experience of having some significant neurotoxicity with these agents. While it’s very hard to predict, once you see it, you can’t forget it. It can manifest in very different forms depending on which part of the brain, which nerve, or which area is inflamed. But having a dedicated multidisciplinary group of experts really helps.

      I really like the idea of giving patients a card so they can inform those providers that they’re on immunotherapy. We’re expanding our education efforts to community site emergency department physicians as well as urgent care facilities. While they may not know what to do right away, at least they can reach out to us, call the main hospital, or call the oncologist on call to get some guidance, because it’s so important to intervene early.

      Transcript edited for clarity.

      Newsletter

      Stay up to date on cancer updates, research and education

      Subscribe Now!
      Related Videos
      The Future of CLL Care: Medical Breakthroughs and Patient-Physician Collaboration
      The Future of CLL Care: Medical Breakthroughs and Patient-Physician Collaboration
      Living Well With CLL: Nutrition, Exercise, and Lifestyle Tips From Patients and Doctors
      Living Well With CLL: Nutrition, Exercise, and Lifestyle Tips From Patients and Doctors
      Fixed-Duration vs Continuous CLL Therapy: Balancing Efficacy, Quality of Life, and Costs
      Fixed-Duration vs Continuous CLL Therapy: Balancing Efficacy, Quality of Life, and Costs
      CLL Treatment and Quality of Life: Patient Empowerment and Shared Decision-making
      CLL Treatment and Quality of Life: Patient Empowerment and Shared Decision-making
      LL Treatment Roadmap: Navigating First-Line Options With Your Doctor
      LL Treatment Roadmap: Navigating First-Line Options With Your Doctor
      Watchful Waiting in CLL: When Waiting Is Treating
      Watchful Waiting in CLL: When Waiting Is Treating
      Connections: CLL Diagnosis: A Patient’s Perspective and Physician Insights
      Connections: CLL Diagnosis: A Patient’s Perspective and Physician Insights
      Connections: Understanding CLL: Symptoms, Diagnosis, and What Patients Need to Know
      Connections: Understanding CLL: Symptoms, Diagnosis, and What Patients Need to Know
      A panel of 3 experts on CML
      Advancing CML Management Towards an Ideal Patient Journey
      Unmet Needs and Challenges in Metastatic Uveal Melanoma
      Unmet Needs and Challenges in Metastatic Uveal Melanoma
      Related Content
      Advertisement
      KCCure Patient Surveys Help Providers Understand Patients’ True Experiences During Treatment
      July 12th 2021

      KCCure Patient Surveys Help Providers Understand Patients’ True Experiences During Treatment

      Jamie Cesanek
      The kidney cancer advocacy organization, KCCure, has been collecting survey data on patient experiences to help bridge the communication gap between providers and patients.
      Related Content
      CURE Expert ConnectionsManagement of Advanced Non–Small Cell Lung Cancer
      CURE Expert Connections
      |
      Management of Advanced Non–Small Cell Lung Cancer
      Advertisement
      KCCure Patient Surveys Help Providers Understand Patients’ True Experiences During Treatment
      July 12th 2021

      KCCure Patient Surveys Help Providers Understand Patients’ True Experiences During Treatment

      Jamie Cesanek
      The kidney cancer advocacy organization, KCCure, has been collecting survey data on patient experiences to help bridge the communication gap between providers and patients.
      Advertisement
      Advertisement
      Advertisement
      x
      About Us
      Advertise / Support
      Editorial Board
      Contact Us
      CancerNetwork.com
      TargetedOnc.com
      OncLive.com
      OncNursingNews.com
      Terms & Conditions
      Privacy
      Do Not Sell My Information
      Contact Info

      2 Commerce Drive
      Cranbury, NJ 08512

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.